Hospitals May Be Unfairly Penalized for Unpreventable Venous Thromboembolism

Article

A study attempting to characterize the true preventability of venous thromboembolism determined that financial penalties based on the total number of patients who suffer blood clots in the lung or leg may be unfairly imposed.

A study attempting to characterize the true preventability of venous thromboembolism (VTE) determined that financial penalties based on the total number of patients who suffer blood clots in the lung or leg may be unfairly imposed.

Researchers with Johns Hopkins University School of Medicine reviewed 128 medical case histories and came to the conclusion that the current pay-for-performance system is a problem. Elliott R. Haut, MD, PhD, an associate professor of surgery at the Johns Hopkins University School of Medicine, explained that even when hospitals do everything they can to prevent VTE, they can still be penalized for patients who develop blood clots.

Nearly half of VTE events identified by the Maryland state program were not truly preventable, he said.

“We know we’re not going to get the VTE rate to zero, but my goal is to have every single one of these events—when they happen—occur when the patient receives best-practice, defect-free care,” Dr Haut said in a statement.

If the findings hold true across the state of Maryland and the rest of the country, hospitals may be penalized millions of dollars through inappropriate fines.

In a research letter published in JAMA Surgery, Dr Haut and his colleagues noted that even with the use of blood thinners and other best practices, some patients will still develop clots. Meanwhile, government regulatory agencies and health insurers are increasingly tracking the number of patients who develop blood clots and imposing financial penalties.

The researchers argue that instead of looking solely at total numbers of patients who develop clots, a better measure would be to track whether patients at risk for clots were appropriately prescribed and given clot-preventing medications.

“To reduce preventable harm, policymakers need to re-evaluate how they penalize hospitals and improve the measures they use to assess VTE prevention performance,” Dr Haut said. “In addition, clinicians need to ensure that patients receive all prescribed preventive therapies.”

Related Videos
Nicolas Ferreyros, Community Oncology Alliance
Vikki Walton, MBA, Mercer
Matthew Crowley, MD, MHS, associate professor of medicine, Duke University School of Medicine.
Dr Seun Ross: Achieving Equity is Necessary to Sustain the Health Care System
Nick Ferreyros, Community Oncology Alliance
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy, Emory Winship Cancer Institute
Kristine Slam, MD, FACP, Central Ohio Surgical Associates
Dr Monica Taylor-Desir on Taking Mental Health Care Awareness to Action
Dr Veronica Gillispie-Bell: We Cannot have Quality Without Equity
Related Content
© 2023 MJH Life Sciences
AJMC®
All rights reserved.